9Carey AL,Lamont B,Andrkopoulos S,et al.Interleukin-6 gene expression is increased in insulin resistan rat skeletal muscle following insulin stimulation[J].Biochem Biophys Res Commun,2003,170(5):302-305.
10Manabe S,Okura T,Watanabe S,et al.Effects of angiotensin Ⅱ receptor blockade with valsartan on pro-inflammatory cytokines in patients with essential hypertension[J].J Cardiovasc Pharmacol,2005,46(6):735-739.
4Kishikawa H,Shimokama T,Watanabe T.Localization of T lymphocytes and macrophages expressing IL-1,IL-2 receptor,IL-6and TNF in human aortic intima.Role of cell-mediated immunity in human atherogensis[J].Virchows Arch Pathol Anat Histopathol,1993,45(4):423-425
5Blay JY,Negrier M,Combaret V,et al.Serum Levels of interleukin-6 as a prognosis factor in matastatic renal cell carcimoma[J].Cancer Res,1992,52(2):3317-3318.
6Carey AL,Lamont B,Andrkopoulos S,et al.Interleukin-6 gene expression is increased in insulin resistomt rat skeletal muscle following insulin stimulation[J].Biochem Biophys Res Commun,2003,170(5):302-305.
7Ndre-Schmutz I,Hindelang C,Bencist C,et al.Cellular and molecular changes accompanying the progression from insulitios to diabetes[J].Eur J Immunol,1999,29(3):245-247.
8Ralston SH.Analysis of gene expression is bone biopsies by polymerase chain reation reaction:evidence fenhanced cytokine expression in postmenopausal osteoporosis[J].J Bone Miner Res,1994,9(6):883.
9Schomin M,Eisenhardt A,Ritz E.Microinflammatory state of uremia[J].Blood Purif,2000,18(4):327.
10Nisbeth N,Hallgren R,Eriksson O,et al.Endotoxemid in chronic renal failure[J].Nephron,1987,45(2):93-94.
3Catena C, Colussi G, Nadalini E, etal. Cardiovascular outcomes in patients with primary aldosteronism after treatment[J]. Arch Intern Med,2008, 168(1) :80-85.
4Sechi LA, Novello M, Lapenna R, et al. Long-term renal outcomes in patients with primary aldosteronism[J]. JAMA, 2006, 295(22) : 2638-2645.
5Brown NJ. Aldosterone and vascular inflammation[J]. Hypertension,2008,15(2) : 161-167.
6Joffe HV, Adler GK. Effect of aldosterone and mineralocorticoid receptor blockade on vascular inflammation[J]. Heart Fail Rev, 2005,10(1):31-37.
7Milliez P, Girerd X, Plouin PF, et al. Evidence for an increased rate of cardiovascular events in patients with primary aldosteronism[J]. J Am Coll Cardiol, 2005,45(8) : 1243-1248.
8Das UN. Hypertension as a low-grade systemic inflammatory condition that has its origins in the perinatal period[J]. J Assoc Physicians lndia,2006,54(2) : 133-142.
9Funder JW, Carey RM, Fardella C, e! al. Case detection, diagnosis, and treatment of patients with primary aldosteronism: an endocrine society clinical practice guideline[J]. J Clin Endoerinol Metab,2008,93(9) :3266-3281.
10Carvaial CA, Herrada AA, Castillo CR, et al. Primary aldosteronism can alter peripheral levels of transforming growth factor-β and tumor necrosis factor-α[J].J Enodoerinol,2009,32(9):759-765.
